<!DOCTYPE html>
<!--[if (gt IE 9)|!(IE)]> <!--> <html lang="en" class="no-js has-comments blog-dealbook section-business"  itemscope xmlns:og="//opengraphprotocol.org/schema/"> <!--<![endif]-->
<!--[if IE 9]> <html lang="en" class="no-js ie9 lt-ie10 has-comments blog-dealbook section-business" xmlns:og="//opengraphprotocol.org/schema/"> <![endif]-->
<!--[if IE 8]> <html lang="en" class="no-js ie8 lt-ie10 lt-ie9 has-comments blog-dealbook section-business" xmlns:og="//opengraphprotocol.org/schema/"> <![endif]-->
<!--[if (lt IE 8)]> <html lang="en" class="no-js lt-ie10 lt-ie9 lt-ie8 has-comments blog-dealbook section-business" xmlns:og="//opengraphprotocol.org/schema/"> <![endif]-->
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var o=n[t]={exports:{}};e[t][0].call(o.exports,function(n){var o=e[t][1][n];return r(o||n)},o,o.exports)}return n[t].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<t.length;o++)r(t[o]);return r}({1:[function(e,n,t){function r(){}function o(e,n,t){return function(){return i(e,[c.now()].concat(u(arguments)),n?null:this,t),n?void 0:this}}var i=e("handle"),a=e(2),u=e(3),f=e("ee").get("tracer"),c=e("loader"),s=NREUM;"undefined"==typeof window.newrelic&&(newrelic=s);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],d="api-",l=d+"ixn-";a(p,function(e,n){s[n]=o(d+n,!0,"api")}),s.addPageAction=o(d+"addPageAction",!0),s.setCurrentRouteName=o(d+"routeName",!0),n.exports=newrelic,s.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(e,n){var t={},r=this,o="function"==typeof n;return i(l+"tracer",[c.now(),e,t],r),function(){if(f.emit((o?"":"no-")+"fn-start",[c.now(),r,o],t),o)try{return n.apply(this,arguments)}finally{f.emit("fn-end",[c.now()],t)}}}};a("setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(e,n){m[n]=o(l+n)}),newrelic.noticeError=function(e){"string"==typeof e&&(e=new Error(e)),i("err",[e,c.now()])}},{}],2:[function(e,n,t){function r(e,n){var t=[],r="",i=0;for(r in e)o.call(e,r)&&(t[i]=n(r,e[r]),i+=1);return t}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],3:[function(e,n,t){function r(e,n,t){n||(n=0),"undefined"==typeof t&&(t=e?e.length:0);for(var r=-1,o=t-n||0,i=Array(o<0?0:o);++r<o;)i[r]=e[n+r];return i}n.exports=r},{}],4:[function(e,n,t){n.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(e,n,t){function r(){}function o(e){function n(e){return e&&e instanceof r?e:e?f(e,u,i):i()}function t(t,r,o,i){if(!d.aborted||i){e&&e(t,r,o);for(var a=n(o),u=m(t),f=u.length,c=0;c<f;c++)u[c].apply(a,r);var p=s[y[t]];return p&&p.push([b,t,r,a]),a}}function l(e,n){v[e]=m(e).concat(n)}function m(e){return v[e]||[]}function w(e){return p[e]=p[e]||o(t)}function g(e,n){c(e,function(e,t){n=n||"feature",y[t]=n,n in s||(s[n]=[])})}var v={},y={},b={on:l,emit:t,get:w,listeners:m,context:n,buffer:g,abort:a,aborted:!1};return b}function i(){return new r}function a(){(s.api||s.feature)&&(d.aborted=!0,s=d.backlog={})}var u="nr@context",f=e("gos"),c=e(2),s={},p={},d=n.exports=o();d.backlog=s},{}],gos:[function(e,n,t){function r(e,n,t){if(o.call(e,n))return e[n];var r=t();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,n,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return e[n]=r,r}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],handle:[function(e,n,t){function r(e,n,t,r){o.buffer([e],r),o.emit(e,n,t)}var o=e("ee").get("handle");n.exports=r,r.ee=o},{}],id:[function(e,n,t){function r(e){var n=typeof e;return!e||"object"!==n&&"function"!==n?-1:e===window?0:a(e,i,function(){return o++})}var o=1,i="nr@id",a=e("gos");n.exports=r},{}],loader:[function(e,n,t){function r(){if(!x++){var e=h.info=NREUM.info,n=d.getElementsByTagName("script")[0];if(setTimeout(s.abort,3e4),!(e&&e.licenseKey&&e.applicationID&&n))return s.abort();c(y,function(n,t){e[n]||(e[n]=t)}),f("mark",["onload",a()+h.offset],null,"api");var t=d.createElement("script");t.src="https://"+e.agent,n.parentNode.insertBefore(t,n)}}function o(){"complete"===d.readyState&&i()}function i(){f("mark",["domContent",a()+h.offset],null,"api")}function a(){return E.exists&&performance.now?Math.round(performance.now()):(u=Math.max((new Date).getTime(),u))-h.offset}var u=(new Date).getTime(),f=e("handle"),c=e(2),s=e("ee"),p=window,d=p.document,l="addEventListener",m="attachEvent",w=p.XMLHttpRequest,g=w&&w.prototype;NREUM.o={ST:setTimeout,SI:p.setImmediate,CT:clearTimeout,XHR:w,REQ:p.Request,EV:p.Event,PR:p.Promise,MO:p.MutationObserver};var v=""+location,y={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-1044.min.js"},b=w&&g&&g[l]&&!/CriOS/.test(navigator.userAgent),h=n.exports={offset:u,now:a,origin:v,features:{},xhrWrappable:b};e(1),d[l]?(d[l]("DOMContentLoaded",i,!1),p[l]("load",r,!1)):(d[m]("onreadystatechange",o),p[m]("onload",r)),f("mark",["firstbyte",u],null,"api");var x=0,E=e(4)},{}]},{},["loader"]);</script>
		<meta name="communityAssetLabels" content="NYT_Blogs" />
<meta name="communityAssetTaxonomy" content="blogs/dealbook/One Day, Two Deals and a Changed Calculus of Deal-Making ( 20141117 )" />
<meta name="communityAssetURL" content="https://dealbook.nytimes.com/2014/11/17/one-day-2-deals-and-a-changed-calculus-of-deal-making/" />
<meta name="PT" content="Blogs" />
<meta name="PST" content="Blog Post" />
<meta name="sourceApp" content="blogs" />
<meta itemprop="identifier" name="blogpostid" content="100000003239974"><meta name="author" content="Steven Davidoff Solomon" />
<meta name="CLMST" content="Steven Davidoff Solomon" />
<meta name="byl" content="Steven Davidoff Solomon" />
<meta name="GBLC" content="Deal Professor;Energy;Financial Services;Healthcare;Hedge Funds;Mergers &amp; Acquisitions">
<meta name="PUV" content="normal" />
<meta property="article:published_time" itemprop="datePublished" content="1416258303" />
<meta name="PUD" content="20141117" />
<meta name="pdate" content="20141117" />
<meta name="ptime" content="20141117160503" />
<meta name="utime" content="20141118022959" />
<meta property="article:modified_time" itemprop="dateModified" content="2014-11-18T02:29:59-05:00" />
<meta name="DISPLAYDATE" content="November 17, 2014" />
<meta name="dat" content="November 17, 2014" />
<meta itemprop="articleSection" property="article:section" content="Business Day" />
<meta name="CG" content="Business Day" />
<meta name="SCG" content="Dealbook" />
<meta name="BN" content="dealbook" />
<meta name="robots" content="noodp">
<meta name="per" content="Ackman, William A">
<meta name="des" content="Mergers, Acquisitions and Divestitures;Shareholder Rights and Activism">
<meta name="org" content="Actavis PLC;Allergan Inc;Baker Hughes Inc;Halliburton Company;Pershing Square Capital Management;Valeant Pharmaceuticals International Inc">
<meta name="ticker" content="Actavis PLC|ACT|NYSE;Allergan Inc|AGN|NYSE;Baker Hughes Inc|BHI|NYSE;Halliburton Company|HAL|NYSE;Valeant Pharmaceuticals International Inc|VRX|NYSE" />
<meta property="article:tag" content="Ackman William A" />
<meta property="article:tag" content="Mergers Acquisitions and Divestitures" />
<meta property="article:tag" content="Shareholder Rights and Activism" />
<meta property="article:tag" content="Actavis PLC" />
<meta property="article:tag" content="Allergan Inc" />
<meta property="article:tag" content="Baker Hughes Inc" />
<meta property="article:tag" content="Halliburton Company" />
<meta property="article:tag" content="Pershing Square Capital Management" />
<meta property="article:tag" content="Valeant Pharmaceuticals International Inc" />
<meta property="article:tag" content="Deal Professor" />
<meta property="article:tag" content="Energy" />
<meta property="article:tag" content="Financial Services" />
<meta property="article:tag" content="Healthcare" />
<meta property="article:tag" content="Hedge Funds" />
<meta property="article:tag" content="Mergers &amp; Acquisitions" />
<meta name="keywords" content="Ackman William A,Mergers Acquisitions and Divestitures,Shareholder Rights and Activism,Actavis PLC,Allergan Inc,Baker Hughes Inc,Halliburton Company,Pershing Square Capital Management,Valeant Pharmaceuticals International Inc,Deal Professor,Energy,Financial Services,Healthcare,Hedge Funds,Mergers &amp; Acquisitions" />
<meta name="news_keywords" content="Mergers and Acquistions,Pershing Square Capital Management,Shareholder Rights,William A Ackman" />
<link rel="alternate" type="application/json+oembed" href="https://www.nytimes.com/svc/oembed/json/?url=https%3A%2F%2Fdealbook.nytimes.com%2F2014%2F11%2F17%2Fone-day-2-deals-and-a-changed-calculus-of-deal-making%2F" title="One Day, Two Deals and a Changed Calculus of Deal-Making" />
<meta name="description" content="As the Allergan and Baker Hughes deals show, companies are struggling to justify a case against activist investors and hostile bidders, Steven Davidoff Solomon writes in the Deal Professor column." />
<meta name="hdl" content="One Day, Two Deals and a Changed Calculus of Deal-Making" />
<meta property="og:title" content="One Day, Two Deals and a Changed Calculus of Deal-Making" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://dealbook.nytimes.com/2014/11/17/one-day-2-deals-and-a-changed-calculus-of-deal-making/" />
<meta property="og:site_name" content="DealBook" />
<meta property="og:description" content="As the Allergan and Baker Hughes deals show, companies are struggling to justify a case against activist investors and hostile bidders, Steven Davidoff Solomon writes in the Deal Professor column." />
<meta property="og:image" content="https://static01.nyt.com/images/2014/11/18/business/dbpix-dealprof3/dbpix-dealprof3-videoSixteenByNine600-v2.jpg"/>
<meta name="thumbnail_150" content="https://static01.nyt.com/images/2014/11/18/business/dbpix-dealprof3/dbpix-dealprof3-thumbLarge-v2.jpg"/>
<meta name="twitter:card" value="summary"><meta name="twitter:title" content="One Day, Two Deals and a Changed Calculus of Deal-Making" />
<meta name="twitter:url" content="https://dealbook.nytimes.com/2014/11/17/one-day-2-deals-and-a-changed-calculus-of-deal-making/" />
<meta name="twitter:description" content="As the Allergan and Baker Hughes deals show, companies are struggling to justify a case against activist investors and hostile bidders, Steven Davidoff Solomon writes in the Deal Professor column." />
<meta name="twitter:image" content="https://static01.nyt.com/images/2014/11/18/business/dbpix-dealprof3/dbpix-dealprof3-thumbLarge-v2.jpg"/>
<meta itemprop="thumbnailUrl" content="https://static01.nyt.com/images/2014/11/18/business/dbpix-dealprof3/dbpix-dealprof3-thumbLarge-v2.jpg" name="thumbnail" />
<meta name="twitter:site" content="@dealbook">
<link rel='prev' title='Another Bitcoin Auction to Be Held by U.S. Marshals' href='https://dealbook.nytimes.com/2014/11/17/another-bitcoin-auction-to-be-held-by-u-s-marshals/' />
<link rel='next' title='Justice Department Is Weighing Civil Suit Against Angelo Mozilo' href='https://dealbook.nytimes.com/2014/11/17/justice-department-is-weighing-civil-suit-against-angelo-mozilo/' />
<link rel='canonical' href='https://dealbook.nytimes.com/2014/11/17/one-day-2-deals-and-a-changed-calculus-of-deal-making/' />
<link rel='shortlink' href='//nyti.ms/1uzXnWi' />
<link rel='https://github.com/WP-API/WP-API' href='https://dealbook.nytimes.com/json' />
<meta name="adxPage" content="blog.nytimes.com/dealbook/post" />
<link rel="alternate" type="application/rss+xml" title="RSS 2.0" href="https://dealbook.nytimes.com/feed/" />
<meta property="article:collection" content="https://static01.nyt.com/services/json/sectionfronts/business/index.jsonp" />
<link rel="alternate" href="//mobile.nytimes.comdealbook/2014/11/17/one-day-2-deals-and-a-changed-calculus-of-deal-making/" />
<meta name="dfp-ad-unit-path" content="businessday/dealbook" />			<title>One Day, Two Deals and a Changed Calculus of Deal-Making - The New York Times</title>
            <!--[if (gt IE 9)|!(IE)]> <!-->
    <link rel="stylesheet" type="text/css" media="screen" href="https://int.nyt.com/assets/blogs/latest/css/blogs/styles.css" />
<!--<![endif]-->
<!--[if lte IE 9]>
    <link rel="stylesheet" type="text/css" media="screen" href="https://int.nyt.com/assets/blogs/latest/css/blogs/styles-ie.css" />
<![endif]-->
<link rel="stylesheet" type="text/css" media="screen" href="https://int.nyt.com/assets/blogs/latest/css/blogs/dealbook.css" />
<link rel="stylesheet" type="text/css" media="print" href="https://int.nyt.com/assets/blogs/latest/css/blogs/styles-print.css" />
<script>
var NYT = NYT || {}, NYTD = NYTD || {};
</script>
                        	<script src="https://int.nyt.com/assets/blogs/latest/js/blogs/layout.js"></script>
	<script type="text/javascript">var googletag=googletag||{};googletag.cmd=googletag.cmd||[],function(){var t=document.createElement("script");t.async=!0,t.type="text/javascript";var e="https:"==document.location.protocol;t.src=(e?"https:":"http:")+"//www.googletagservices.com/tag/js/gpt.js";var o=document.getElementsByTagName("script")[0];if (!/NYT-T=out/.test(document.cookie)) {o.parentNode.insertBefore(t,o)}}();</script>
<script id="magnum-feature-flags" type="application/json">["limitFabrikSave","facebookOauthButton","videoVHSCover","videoVHSShareTools","videoVHSEmbeddedOnly","removeInternationalEdition","piiBlockDFP","indexAsHeaderBidder","caslOpt"]</script>
<script>
var require = {
    baseUrl: 'https://int.nyt.com/assets/',
    waitSeconds: 20,
    paths: {
        'foundation': 'blogs/latest/js/foundation',
        'shared': 'blogs/latest/js/shared',
        'blogs': 'blogs/latest/js/blogs',
        'auth/mtr': 'https://static01.nyt.com/js/mtr',
        'auth/growl': 'https://static01.nyt.com/js/auth/growl/default',
        'vhs': 'https://static01.nyt.com/video/vhs/build/vhs-2.x.min'
    }
};
</script>
<!--[if (gte IE 9)|!(IE)]> <!-->
<script data-main="foundation/main" src="https://int.nyt.com/assets/blogs/latest/js/foundation/lib/framework.js"></script>
<!--<![endif]-->
<!--[if lt IE 9]>
<script>
require.map = { '*': { 'foundation/main': 'foundation/legacy_main' } };
</script>
<script data-main="foundation/legacy_main" src="https://int.nyt.com/assets/blogs/latest/js/foundation/lib/framework.js"></script>
<![endif]-->
<script>
require(['foundation/main'], function () {
    require(['auth/mtr']);
});
</script>
<!--esi
<script id="user-info-data" type="application/json">
<esi:include src="/svc/web-products/userinfo-v3.json" />
</script>
-->
    	</head><body class="single single-post postid-637777 blog-universal nyt-blog-dealbook" id="" data-env="production" data-region="ewr1">
	<div id="shell" class="shell">
			<header id="masthead" class="masthead masthead-theme-standard" role="banner">
    <div class="container">
        <div class="quick-navigation button-group">
            <button class="button sections-button"><i class="icon sprite-icon"></i><span class="button-text">Sections</span></button>
            <button class="button home-button" data-href="https://www.nytimes.com/" title="Go to the home page to see the latest top stories."><i class="icon sprite-icon"></i>
                <span class="button-text">Home</span>
            </button>
            <button class="button search-button"><i class="icon sprite-icon"></i><span class="button-text">Search</span></button>
            <a class="button skip-button skip-to-content visually-hidden focusable" href="#main">Skip to content</a>
                                </div><!-- close button-group -->
        <div class="branding">
            <h2 class="branding-heading">
                <a id="branding-heading-link" href="https://www.nytimes.com/">
                    <span class="visually-hidden">The New York Times</span>
                </a>
            </h2>
            <script>window.magnum.writeLogo('small', 'https://int.nyt.com/assets/blogs/latest/images/foundation/logos/', 'Business Day', 'masthead-theme-standard', 'standard', 'branding-heading-link', 'blogs');</script>
        </div><!-- close branding -->
        <div class="story-meta">
    <h6 class="kicker">
        <span class="kicker-label">
			            <a href="https://dealbook.nytimes.com">
                DealBook            </a>
			        </span>

                <span class="pipe">|</span>
        One Day, Two Deals and a Changed Calculus of Deal-Making        
    </h6>
</div><!-- close story-meta -->


        <div class="user-tools">
            <div id="Bar1" class="ad bar1-ad nocontent robots-nocontent"></div>
            <div id="sharetools-masthead" class="sharetools theme-classic"
	 data-shares="email,facebook,twitter,show-all|More"
	 data-url="https://dealbook.nytimes.com/2014/11/17/one-day-2-deals-and-a-changed-calculus-of-deal-making/"
	 data-title="One Day, Two Deals and a Changed Calculus of Deal-Making"
	 data-description="&lt;span class=&quot;excerpt-inner&quot;&gt;As the Allergan and Baker Hughes deals show, companies are struggling to justify a case against activist investors and hostile bidders, Steven Davidoff Solomon writes in the Deal Professor column. &lt;/span&gt;&lt;a href=&quot;https://dealbook.nytimes.com/2014/11/17/one-day-2-deals-and-a-changed-calculus-of-deal-making/&quot; class=&quot;more-link&quot;&gt;Read&nbsp;more...&lt;/a&gt;"
	data-publish-date="November 17, 2014 4:05 pm">
<div class="ad sharetools-inline-article-ad hidden"></div>
</div><!-- close shareTools -->
            <button class="button search-button"><i class="icon sprite-icon"></i><span class="button-text">Search</span></button>
            <div class="user-tools-button-group button-group">
                <button class="button subscribe-button hidden" data-href="https://www.nytimes.com/subscriptions/Multiproduct/lp3004.html?campaignId=4XUYF">Subscribe Now</button>
                <button class="button login-button login-modal-trigger hidden">Log In</button>
                <button class="button comments-button  button-masthead" data-skip-to-para-id="">
</button>
                                <button class="button notifications-button hidden"><i class="icon sprite-icon"></i><span class="button-text">0</span></button>
                <button class="button user-settings-button"><i class="icon sprite-icon"></i><span class="button-text">Settings</span></button>
            </div><!-- close user-tools-button-group -->
        </div><!-- close user-tools -->
    </div><!-- close container -->
    <div class="search-flyout-panel flyout-panel">
    <button class="button close-button" type="button"><i class="icon"></i><span class="visually-hidden">Close search</span></button>
    <nav class="search-form-control form-control layout-horizontal">
    <h2 class="visually-hidden">Site Search Navigation</h2>
    <form class="search-form" role="search">
        <div class="control">
            <div class="label-container visually-hidden">
                                <label for="search-input">Search NYTimes.com</label>
                            </div>
            <div class="field-container">
                                <input id="search-input" name="search-input" type="text" class="search-input text" autocomplete="off" placeholder="Search NYTimes.com" />
                
                <button type="button" class="button clear-button" tabindex="-1" aria-describedby="clear-search-input"><i class="icon"></i><span id="clear-search-input" class="visually-hidden">Clear this text input</span></button>
                <div class="auto-suggest" style="display: none;">
                    <ol></ol>
                </div>
                <button class="button submit-button" type="submit">Go</button>
            </div>
        </div><!-- close control -->
    </form>
</nav>


</div><!-- close flyout-panel -->
    <div id="notification-modals" class="notification-modals"></div>
</header>
					<nav id="ribbon" class="ribbon ribbon-start nocontent robots-nocontent" aria-hidden="true">
    <div class="nocontent robots-nocontent">
        <ol class="ribbon-menu">
            <li class="collection ribbon-loader">
                <div class="loader "><span class="visually-hidden">Loading...</span></div>
            </li>
        </ol>
        <div class="ribbon-navigation-container">
            <nav class="ribbon-navigation next">
                <span class="visually-hidden">See next articles</span>
                <div class="arrow arrow-right">
                    <div class="arrow-conceal"></div>
                </div>
            </nav>
            <nav class="ribbon-navigation previous">
                <span class="visually-hidden">See previous articles</span>
                <div class="arrow arrow-left">
                    <div class="arrow-conceal"></div>
                </div>
            </nav>
        </div>
    </div><!-- close nocontent -->
</nav>
						<nav id="navigation" class="navigation">
    <h2 class="visually-hidden">Site Navigation</h2>
</nav><!-- close navigation -->

<nav id="mobile-navigation" class="mobile-navigation hidden">
    <h2 class="visually-hidden">Site Mobile Navigation</h2>
</nav><!-- close mobile-navigation -->

    <div id="navigation-edge" class="navigation-edge"></div>
				<main id="main" class="main" role="main">
				<div id="TopAd" class="ad top-ad"></div>
				<div id="mobilebanner" class="ad mobilebanner"></div>
								<div id="story" class="story theme-main">
		<div id="dealbook" class="spanAC blog">
			<header id="blogs-masthead" class="wrap">
	<div class="ad sponsortile-ad hidden nocontent robots-nocontent">
		<div class="caption">Supported by</div>
		<div id="sponsortile" class="ad sponsortile-ad-creative"></div>
	</div>
		<div class="element1">
	<div id="logo" ><a href="https://dealbook.nytimes.com/?module=BlogMain&action=Click&region=Header&pgtype=Blogs&version=Blog Post&contentCollection=Business Day" title="Go to DealBook Home"><img src="https://static01.nyt.com/images/blogs_v5/dealbook/dealbook_post.png" alt="DealBook - A Financial News Service of The New York Times"/></a></div>    </div>
    <div class="element2">
    <div class="inlineSearchControl">
	<form method="get" id="searchform" action="https://dealbook.nytimes.com/">
		<input type="text" value="" name="s" id="s" class="text" placeholder="Search DealBook">
		<button type="submit" class="searchsubmit">Search</button>
	</form>
</div>	</div>
	<div class="clear"></div>
		<div id="topic-nav">
		<ul>
			<li class="first"><a href="https://dealbook.nytimes.com/category/main-topics/mergers-acquisitions/">Mergers &amp; Acquisitions</a></li>
			<li><a href="https://dealbook.nytimes.com/category/main-topics/investment-banking/">Investment Banking</a></li>
			<li><a href="https://dealbook.nytimes.com/category/main-topics/private-equity/">Private Equity</a></li>
			<li><a href="https://dealbook.nytimes.com/category/main-topics/hedge-funds/">Hedge Funds</a></li>
			<li><a href="https://dealbook.nytimes.com/category/main-topics/ipoofferings/">I.P.O./Offerings</a></li>
			<li><a href="https://dealbook.nytimes.com/category/main-topics/venture-capital/">Venture Capital</a></li>
			<li class="last"><a href="https://dealbook.nytimes.com/category/main-topics/legal/">Legal/Regulatory</a></li>
		</ul>
	</div>
		</header>
	<div class="a-column " id="a-col">
	<div id="content" class="hfeed">
	<article class="post-637777 post type-post status-publish hentry category-deal-professor category-energy-by-industry-2 category-financial-services category-healthcare category-hedge-funds category-mergers-acquisitions tag-ackman-william-a tag-actavis-plc tag-allergan-inc tag-baker-hughes-inc tag-halliburton-company tag-mergers-acquisitions-and-divestitures tag-pershing-square-capital-management tag-shareholder-rights-and-activism tag-valeant-pharmaceuticals-international-inc per-ackman-william-a des-mergers-acquisitions-and-divestitures des-shareholder-rights-and-activism org-actavis-plc org-allergan-inc org-baker-hughes-inc org-halliburton-company org-pershing-square-capital-management org-valeant-pharmaceuticals-international-inc news_keywords-mergers-and-acquistions news_keywords-pershing-square-capital-management news_keywords-shareholder-rights news_keywords-william-a-ackman-2" id="post-637777">
	<header class="postHeader">
				<div class="postKicker">
			<span class="kicker"><a href="https://dealbook.nytimes.com/category/main-topics/hedge-funds/">Hedge Funds</a> | <a href="https://dealbook.nytimes.com/category/columnists/deal-professor/">Deal Professor</a></span>		</div>
				<h1 itemprop="headline" class="entry-title">One Day, Two Deals and a Changed Calculus of Deal-Making</h1>
		<div class="story-meta-footer">
			<address class="byline author vcard" itemprop="author creator" itemtype="//schema.org/Person">
				By Steven Davidoff Solomon			</address>
			<!-- date published --><time class="dateline " datetime="2014-11-17T21:05:03+00:00" itemprop="datePublished">November 17, 2014 4:05 pm</time>
			<!-- date updated --><span class="visually-hidden updated">November 17, 2014 4:05 pm</span><button class="button comments-button  theme-kicker" data-skip-to-para-id="">
</button>
		</div>
			</header>
		<div class="entry-content">
	<div id="sharetools-story" class="sharetools theme-classic sharetools-story" data-shares="email|Email,facebook|Share,twitter|Tweet,save|Save,show-all|More,ad" data-url="https://dealbook.nytimes.com/2014/11/17/one-day-2-deals-and-a-changed-calculus-of-deal-making/" data-title="One Day, Two Deals and a Changed Calculus of Deal-Making" data-description="As the Allergan and Baker Hughes deals show, companies are struggling to justify a case against activist investors and hostile bidders, Steven Davidoff Solomon writes in the Deal Professor column. ">
				<div class="ad sharetools-inline-article-ad"></div>
				<div id="MiddleLeft" class="ad middle-left-ad nocontent robots-nocontent"></div>
				</div><div class="w190 right"><figure class="media photo promo" itemprop="" itemscope="" itemid="https://static01.nyt.com/images/2014/11/18/business/dbpix-dealprof2/dbpix-dealprof2-articleInline.jpg" itemtype="//schema.org/ImageObject" role="group"><span class="visually-hidden">Photo</span><div class="image"><img itemprop="url" itemid="https://static01.nyt.com/images/2014/11/18/business/dbpix-dealprof2/dbpix-dealprof2-articleInline.jpg" src="https://static01.nyt.com/images/2014/11/18/business/dbpix-dealprof2/dbpix-dealprof2-articleInline.jpg" id="100000003239964" width="190" height="190" alt=""   /><meta itemprop="height" content="190"><meta itemprop="width" content="190"></div><figcaption class="caption" itemprop="description"><span class="caption-text"></span><span class="credit" itemprop="copyrightHolder"><span class="visually-hidden">Credit</span> Harry Campbell</span></figcaption></figure></div>
<p class="story-body-text" itemprop="articleBody">It has been awhile since weâve seen a deal day like Monday, with <a href="//dealbook.nytimes.com/2014/11/17/halliburton-to-buy-baker-hughes-for-34-billion/" title="Halliburton to Buy Baker Hughes for $34.6 Billion">Halliburton announcing that it had reached a $34.6 billion deal to buy Baker Hughes</a> and <a href="//dealbook.nytimes.com/2014/11/17/allergan-agrees-to-be-sold-to-actavis/" title="Botox Maker Allergan Agrees to Be Sold to Actavis">Allergan selling itself to Actavis for $66 billion</a>. The deals show that the merger and acquisitions market is changing in some obvious and not so obvious ways that may change how companies are bought and sold. </p>
<p class="story-body-text" itemprop="articleBody">The obvious change is the role of shareholders and shareholder activists, as illustrated by <a href="//dealbook.on.nytimes.com/public/overview?symbol=AGN&#038;inline=nyt-org" class="tickerized" title="More information about Allergan Inc">Allergan</a>âs sale. In this case, the hedge fund Pershing Square Capital Management served an invaluable role as a handmaiden to Allerganâs perhaps forced sale. The presence of a shareholder activist in a hostile deal startled the market. But like many a good idea, it was obvious in hindsight. </p>
<p class="story-body-text" itemprop="articleBody">The shareholder activist <a href="//topics.nytimes.com/top/reference/timestopics/people/i/carl_c_icahn/index.html?inline=nyt-per" class="tickerized" title="More articles about Carl C. Icahn.">Carl C. Icahn</a>, for example, has made billions in taking a position in a company and orchestrating a sale. So why not just work beforehand with a bidder &#8212; in this case, <a href="//dealbook.on.nytimes.com/public/overview?symbol=VRX&#038;inline=nyt-org" class="tickerized" title="More information about Valeant Pharmaceuticals International Inc">Valeant Pharmaceuticals International</a>? </p>
<p class="story-body-text" itemprop="articleBody">For Pershing, William A. Ackman&#8217;s hedge fund, the result is a $2.6 billion profit in Allerganâs sale.  </p>
<p class="story-body-text" itemprop="articleBody">This profit also highlights how shareholder pressure is greatly benefiting the activists. A handful of institutional shareholders now typically control any company, and they tend to side with the activists. The targeted company ends up on its back foot, struggling to make a counterargument. And so Allergan was heading to a Dec. 18 special shareholders meeting where it appeared to be in a losing situation, about to have several, if not all, of its directors thrown out. </p>
<p class="story-body-text" itemprop="articleBody">Faced with this, Allergan beat the bushes and found a blockbuster bid. I must admit, <a href="//dealbook.nytimes.com/2014/08/12/in-allergan-fight-a-focus-on-clever-strategy-overshadows-the-goal/">I had questioned the decision</a> by Pershing Square and Valeant to seek a special meeting instead of forcing the issue in Allerganâs meeting in May. But in retrospect, it turns out that this was a good maneuver.  Normally, time is not on hostile bidderâs side. But here, Pershing Square could sit back and wait, knowing that it was giving more time for another bidder to come in. Allergan had an incentive to act because Pershing Square was not about to go away even if Valeant gave up. Pershing Square succeeded in flipping the drivers of a hostile bid.   </p>
<p class="story-body-text" itemprop="articleBody">As for Valeant, it will take away $389 million, enough to pay its advisers and pay itself $100 million or so. Itâs not a great payday but still sufficient to make it feel better about its loss. And with <a href="//dealbook.on.nytimes.com/public/overview?symbol=ACT&#038;inline=nyt-org" class="tickerized" title="More information about Actavis PLC.">Actavis</a> having set the bidding price, Valeant now has the option (which it promptly declined to do in a statement) to offer a higher bid and take Allergan. In other words, the Pershing Square gambit gave Valeant more options than it normally would have had in a hostile bid, and a greater chance to succeed. </p>
<p class="story-body-text" itemprop="articleBody">Pershing Squareâs huge profit mean that this tactic will probably be repeated, though modified in future hostile bids to deal with some of the flaws that arose in this battle. You wonât see many tender offers made when a bidder pairs with a hedge fund, for instance, forestalling the insider trading claims that were brought in this deal (and remain pending). And perhaps the hostile bidder will demand more of the profits. Left unanswered is whether this type of jiujitsu is good for companies. With hedge funds playing dual roles as both major shareholder and hostile bidder, they will foster an active takeover market and reap gains for shareholders. That&#8217;s the ultimate goal, but you canât help feeling a touch squeamish.</p>
<p class="story-body-text" itemprop="articleBody">That leads to the less obvious lesson in <a href="//dealbook.on.nytimes.com/public/overview?symbol=HAL&#038;inline=nyt-org" class="tickerized" title="More information about Halliburton Company">Halliburton</a>âs deal for a rival oil field services provider <a href="//dealbook.on.nytimes.com/public/overview?symbol=BHI&#038;inline=nyt-org" class="tickerized" title="More information about Baker Hughes Inc">Baker Hughes</a>. On Friday, this deal looked to be heading to a situation similar to Allergan&#8217;s with Valeant. Halliburton had timed its bid perfectly to allow for it to nominate directors and unseat the Baker Hughes board.    </p>
<p class="story-body-text" itemprop="articleBody">Baker Hughes resisted, noting Halliburtonâs failure in negotiations to raise its offer and the lack of a termination fee, payable by Halliburton, if the deal didnât clear an antitrust review. This is a big risk when the No. 2 and 3 competitors in an industry merge, as is the case here. </p>
<p class="story-body-text" itemprop="articleBody">But before being forced into a full-fledged hostile situation, Baker Hughes caved. In part, this is because Halliburton did what Valeant didnât want to do &#8212; pay full price.  Not only did Halliburton pay full price, it agreed to a $3.5 billion reverse termination fee if the deal didnât clear antitrust hurdles.  </p>
<p class="story-body-text" itemprop="articleBody">This is 10 percent of the transaction value and a rich number to compensate Baker Hughes. Faced with a full bid and its terms met, Baker Hughes could have said no, but it would have faced that proxy contest. So it quickly capitulated. Halliburton cut short a prolonged fight by applying all the pressures and getting it right. </p>
<p class="story-body-text" itemprop="articleBody">The Halliburton deal shows the not-so-obvious point that in the new shareholder-centric world, companies are struggling to justify a case against not just an activist but also a hostile bidder. You can like this or not, but it is a fact, and the presumption is against the targeted company.  </p>
<p class="story-body-text" itemprop="articleBody">So where does that leave us? </p>
<p class="story-body-text" itemprop="articleBody">Hostile takeovers are recovering from a near-death experience, though they are still likely to be unusual. These two deals show that the justification needs to be there. For Halliburton, this is a consolidating industry and the economies of scale of acquiring your next biggest competitor are huge. For Actavis, the pharmaceutical industry is near the end of a frenzy of deal-making as mergers and acquisitions substitute for drug development. Chief executives will be careful to justify the need and the expense, but now may be more prone to do a deal if an activist is there (or has the potential).</p>
<p class="story-body-text" itemprop="articleBody">The shareholders and activists who do these deals are here to stay. Expect more creative and unusual tactics and more litigation as companies push back or perhaps realize the inevitable and accede. As Pershing Square&#8217;s $2.6 billion profit shows, there is too much money at stake, and there will be more deals like this in the future, perhaps many more. </p>
<p class="story-body-text" itemprop="articleBody">Meanwhile, companies will struggle with how and when to respond. </p>
			<div class="nyt-article-promo">
								<div class="w190">
					<a href="//dealbook.nytimes.com/2014/11/17/allergan-agrees-to-be-sold-to-actavis/?ref=dealbook"><img src="https://static01.nyt.com/images/2014/11/18/business/Drugjp/Drugjp-thumbWide.jpg" width="190" height="126" alt="Allergan Escapes Valeantâs Pursuit, Agreeing to Be Bought by Actavis" /></a>
				</div>
                				<h4><a href="//dealbook.nytimes.com/2014/11/17/allergan-agrees-to-be-sold-to-actavis/?ref=dealbook">Allergan Escapes Valeantâs Pursuit, Agreeing to Be Bought by Actavis</a></h4>
				<p class="nyt-article-byline">By DAVID GELLES</p>
				<p class="nyt-article-summary">The $66 billion acquisition by Actavis would be the largest deal this year and would thwart the takeover effort of Valeant and William A. Ackman.</p>
			</div>
			
			<div class="nyt-article-promo">
								<div class="w190">
					<a href="//dealbook.nytimes.com/2014/11/17/halliburton-to-buy-baker-hughes-for-34-billion/?ref=dealbook"><img src="https://static01.nyt.com/images/2014/11/18/business/dbpix-baker1/dbpix-baker1-thumbWide.jpg" width="190" height="126" alt="Halliburton and Baker Hughes Agree to Friendly $34.6 Billion Merger" /></a>
				</div>
                				<h4><a href="//dealbook.nytimes.com/2014/11/17/halliburton-to-buy-baker-hughes-for-34-billion/?ref=dealbook">Halliburton and Baker Hughes Agree to Friendly $34.6 Billion Merger</a></h4>
				<p class="nyt-article-byline">By MICHAEL J. DE LA MERCED</p>
				<p class="nyt-article-summary">Together, the two are expected to save nearly $2 billion in costs through a combination of operations and research and development.</p>
			</div>
			
<footer class="story-footer">
    <div class="story-meta">
	    </div>
</footer>
	</div>
		<footer class="entry-footer">
			<button class="button comments-button theme-speech-bubble"></button>		<div id="sharetools-post-footer" class="sharetools theme-classic" data-shares="show-all|Share" data-url="https://dealbook.nytimes.com/2014/11/17/one-day-2-deals-and-a-changed-calculus-of-deal-making/" data-title="One Day, Two Deals and a Changed Calculus of Deal-Making" data-description="As the Allergan and Baker Hughes deals show, companies are struggling to justify a case against activist investors and hostile bidders, Steven Davidoff Solomon writes in the Deal Professor column. ">
				<div class="ad sharetools-inline-article-ad hidden"></div>
			</div>		<div class="footer-tags">
					</div>
		</footer>
</article>
		<section id="whats-next" class="whats-next nocontent robots-nocontent">
    <h2 class="visually-hidden">What's Next</h2>
    <div class="nocontent robots-nocontent">
        <div class="loader-container">
            <div class="loader loader-t-logo-32x32-ecedeb-ffffff"><span class="visually-hidden">Loading...</span></div>
        </div>
    </div><!-- close nocontent -->
</section>

			</div><!-- end content -->
</div><!-- end .a-column -->
<div class="cColumn nocontent robots-nocontent">
	<aside>
	<div class="postNavigation">
	<ul class="opposingFloatControl wrap">
		<li class="element1">
						<span class="previous">Previous Post</span>
			<div class="arrow arrow-left">
				<div class="arrow-conceal"></div>
			</div>
			<a class="postTitle" href="https://dealbook.nytimes.com/2014/11/17/another-bitcoin-auction-to-be-held-by-u-s-marshals/" title="Another Bitcoin Auction to Be Held by U.S. Marshals">
				Another Bitcoin Auction to Be Held by U.S. Marshals			</a>
					</li>
		<li class="element2">
						<span class="next">Next Post</span>
			<div class="arrow arrow-right">
				<div class="arrow-conceal"></div>
			</div>
			<a class="postTitle" href="https://dealbook.nytimes.com/2014/11/17/justice-department-is-weighing-civil-suit-against-angelo-mozilo/" title="Justice Department Is Weighing Civil Suit Against Angelo Mozilo">
				Justice Department Is Weighing Civil Suit Against Angelo Mozilo			</a>
					</li>
	</ul>
</div>
		<div class="module ad" id="MiddleRight"></div>
        	</aside>
</div>		<div class="clear"></div>
	</div><!-- end blog wrap -->
	<div class="hideContent"></div>

	
<!-- Google Analytics start -->
<script type="text/javascript">
(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;if (!/NYT-T=out/.test(document.cookie)) {m.parentNode.insertBefore(a,m)} })(window,document,'script','//www.google-analytics.com/analytics.js','ga');
ga('create', 'UA-4406282-12',  { 'alwaysSendReferrer': true } );
ga('send', 'pageview');
</script>
<!-- Google Analytics end -->
		<div id="mobilebanner2" class="ad mobilebanner2"></div>
		<div class="accessibility-ad-header visually-hidden">
    <p>Advertisement</p>
</div>
<div id="SponLink" class="text-ad bottom-left-ad nocontent robots-nocontent"></div>

		<div id="Top5" class="ad top5-ad hidden nocontent robots-nocontent"></div>

					</div>
			<div class="search-overlay"></div>
		</main><!-- close main -->
						<footer id="page-footer" class="page-footer" role="contentinfo">
    <nav>
         <ul>
             <li>
                <a href="https://www.nytco.com" itemprop="copyrightNotice">
                    &copy; <span itemprop="copyrightYear">2017</span>
					<span itemprop="copyrightHolder provider sourceOrganization" itemscope
						itemtype="//schema.org/Organization"
						itemid="//www.nytimes.com">
						<span itemprop="name"> The New York Times Company</span>
						<meta itemprop="tickerSymbol" content="NYSE NYT"/>
					</span>
                </a>
            </li>
            <li><a href="https://www.nytimes.com/ref/membercenter/help/infoservdirectory.html">Contact Us</a></li>
            <li><a href="//www.nytco.com/careers/">Work With Us</a></li>
            <li><a href="//nytmediakit.com/">Advertise</a></li>
            <li><a href="https://www.nytimes.com/content/help/rights/privacy/policy/privacy-policy.html#pp">Your Ad Choices</a></li>
            <li><a href="https://www.nytimes.com/privacy">Privacy</a></li>
            <li><a href="https://www.nytimes.com/ref/membercenter/help/agree.html" itemprop="usageTerms">Terms of Service</a></li>
            <li class="last-item"><a href="https://www.nytimes.com/content/help/rights/sale/terms-of-sale.html">Terms of Sale</a></li>
         </ul>
    </nav>
    <nav class="last-nav">
        <ul>
            <li><a href="//spiderbites.nytimes.com">Site Map</a></li>
            <li><a href="https://www.nytimes.com/membercenter/sitehelp.html">Help</a></li>
            <li><a href="https://myaccount.nytimes.com/membercenter/feedback.html">Site Feedback</a></li>
            <li class="last-item"><a href="https://www.nytimes.com/subscriptions/Multiproduct/lp5558.html?campaignId=37WXW">Subscriptions</a></li>
        </ul>
    </nav>
</footer>		</div><!-- close shell -->
	<script>
require(['foundation/main'], function () {
    require(['blogs/main']);
    require(['jquery/nyt', 'foundation/views/page-manager'], function ($, pageManager) {
        if (window.location.search.indexOf('disable_tagx') > 0) {
            return;
        }
        $(document).ready(function () {
            require(['https://a1.nyt.com/analytics/json-kidd.min.js'], function () {
                pageManager.trackingFireEventQueue();
            });
        });
    });
});
</script>

	<div id="Inv1" class="ad inv1-ad hidden"></div>
<div id="Inv2" class="ad inv2-ad hidden"></div>
<div id="Inv3" class="ad inv3-ad hidden"></div>
<div id="ab1" class="ad ab1-ad hidden"></div>
<div id="ab2" class="ad ab2-ad hidden"></div>
<div id="ab3" class="ad ab3-ad hidden"></div>
<div id="prop1" class="ad prop1-ad hidden"></div>
<div id="prop2" class="ad prop2-ad hidden"></div>
<div id="Anchor" class="ad anchor-ad hidden"></div>
<div id="ADX_CLIENTSIDE" class="ad adx-clientside-ad hidden"></div>
		<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","licenseKey":"b5bcf2eba4","applicationID":"5164608","transactionName":"YwFXZhRYVhAEVUZcX1pLYEAPFlkTFRtQWV9TFxtCDkk=","queueTime":0,"applicationTime":53,"ttGuid":"","agentToken":"","userAttributes":"","errorBeacon":"bam.nr-data.net","agent":""}</script></body>
</html>
